Analysts Set Smith & Nephew SNATS, Inc. (NYSE:SNN) PT at $35.75

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have been assigned an average recommendation of “Hold” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $35.75.

SNN has been the topic of several recent analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, January 21st. Royal Bank Of Canada lowered shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th. Wall Street Zen upgraded shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 10th. Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a research report on Monday, November 17th. Finally, Canaccord Genuity Group reduced their price objective on shares of Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating for the company in a research note on Tuesday, November 11th.

Institutional Investors Weigh In On Smith & Nephew SNATS

Several large investors have recently made changes to their positions in the stock. Garner Asset Management Corp acquired a new position in Smith & Nephew SNATS during the fourth quarter worth $27,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Smith & Nephew SNATS during the 3rd quarter worth about $41,000. AlphaCore Capital LLC acquired a new position in shares of Smith & Nephew SNATS during the 2nd quarter worth about $44,000. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Smith & Nephew SNATS by 105.8% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 1,385 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 712 shares during the period. Finally, Huntington National Bank boosted its stake in shares of Smith & Nephew SNATS by 1,837.0% during the 3rd quarter. Huntington National Bank now owns 1,414 shares of the medical equipment provider’s stock worth $51,000 after acquiring an additional 1,341 shares during the period. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew SNATS Trading Down 0.4%

NYSE:SNN opened at $35.23 on Monday. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. Smith & Nephew SNATS has a 1-year low of $23.91 and a 1-year high of $38.79. The business’s 50-day moving average price is $33.36 and its two-hundred day moving average price is $34.73.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.